- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/20 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
Patent holdings for IPC class C07D 239/20
Total number of patents in this class: 56
10-year publication summary
|
3
|
3
|
6
|
8
|
4
|
2
|
4
|
2
|
2
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| VALO Health, Inc. | 169 |
5 |
| Enanta Pharmaceuticals, Inc. | 428 |
4 |
| Bristol-myers Squibb Company | 4875 |
3 |
| Takeda Pharmaceutical Company Limited | 2938 |
3 |
| Janssen Sciences Ireland Unlimited Company | 435 |
3 |
| Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | 188 |
2 |
| Paratek Pharmaceuticals, Inc. | 112 |
2 |
| Universite de Montreal | 345 |
2 |
| The Walter and Eliza Hall Institute of Medical Research | 172 |
2 |
| Merck Sharp & Dohme LLC | 3758 |
2 |
| BASF SE | 20565 |
1 |
| Merck Sharp & Dohme Corp. | 2213 |
1 |
| Commissariat à l'énergie atomique et aux energies alternatives | 10720 |
1 |
| Allergan Sales, LLC | 257 |
1 |
| Astex Therapeutics Limited | 251 |
1 |
| Beijing Molecule Science and Technology Co., Ltd. | 12 |
1 |
| Cristalia Produtos Quimicos Farmaceuticos Ltda. | 29 |
1 |
| Doosan Corporation | 432 |
1 |
| Epizyme, Inc. | 387 |
1 |
| Fochon Pharma, Inc. | 1 |
1 |
| Other owners | 18 |